Trial reportESMO open2025
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry.
Trial report in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe PlanB registry evaluated long-term follow-up data for clinical candidates for chemotherapy enrolled in the PlanB trial in hormone receptor (HR)-positive early breast cancer (eBC) patients preselected using the 21-gene expression assay. PATIENTS AND
methodsPlanB randomly assigned pT1-4c, pN+, pN0/high-risk human epidermal growth factor receptor 2 (HER2)-negative eBC patients to four cycles of epirubicin + cyclophoshamide followed by four cycles of docetaxel (EC-T arm) or to six cycles of docetaxel + cyclophosphamide (TC); patients with locally HR-positive tumors and recurrence score (RS) <12 received endocrine therapy (ET) only. Following the end of PlanB, patients with HR-positive tumors were included in a prospective, noninterventional PlanB registry. The primary objective was to compare invasive disease-free survival (iDFS); the secondary objectives were the comparisons of overall survival (OS), and distant disease-free survival (dDFS).
resultsThe registry included 699 patients (ET only: n = 119, TC: n = 298, EC-T: n = 289). In the TC and EC-T groups, respectively, 41% and 41% were postmenopausal; 63% and 55% were pN0; and 23% and 24% had RS >25. Ten-year survival rates (10.3 years median follow-up) in the TC and EC-T arms were, respectively, 90.8% [95% confidence interval (CI) 86.6% to 93.7%] and 92.1% (95% CI 88.2% to 94.7%, P = 0.546) for iDFS; 94.4% (95% CI 90.9% to 96.5%) and 93.2% (95% CI 89.5% to 95.6%, P = 0.789) for dDFS, and 96.8% (95% CI 94.0% to 98.3%) and 96.3% (95% CI 93.3% to 98.0%, P = 0.974) for OS. Overall, 10-year OS was 94.2% (95% CI 88.9% to 97.1%) in RS <12 (77.9% received ET-only), 96.8% (95% CI 94.4% to 98.2%) in RS 12-25, and 96.1% (95% CI 90.9% to 98.4%) in RS >25 group. RS was not predictive of the efficacy of EC-T versus TC.
conclusionsTen-year outcomes for TC and EC-T were similar and excellent; six cycles of TC is an effective option in HER2-negative eBC with pN0 or pN1 and intermediate-to-high-risk disease, according to gene expression analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.